U.S. Stocks in Motion | Bambusa Therapeutics (BBTX.US) Debuts on U.S. Stock Market, Shares Fall Over 8%

Zhitong Finance APP has learned that on Friday, Bambusa Therapeutics (BBTX.US) listed on the U.S. stock market. As of press time, the stock fell more than 8% to $14.685. The IPO price was $16. Bambusa Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, USA, focused on developing next-generation long-acting bispecific antibody drugs for the treatment of immune system and inflammatory diseases. These drugs can simultaneously target two disease-related biological targets, aiming to improve therapeutic efficacy, extend duration of effect, and reduce patient dosing frequency. The company's main investigational drug BBT001 is used to treat skin diseases such as atopic dermatitis (eczema) and chronic spontaneous urticaria; another candidate drug BBT002 mainly targets inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. In addition, the company is also developing early-stage drugs for inflammatory bowel disease and autoimmune diseases.